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ABSTRACT 
 
Anti-tumor effect induced by both DNA vaccine and 
oncolytic adenovirus expressing multi-target genes related to immunity 
in malignant melanoma 
 
 
Soyoung Kim 
 
Department of Medical Science 
The Graduate School, Yonsei University  
 
(Directed by Professor Joo-Hang Kim) 
 
 
Immunogene therapy is an immune system-mediated strategy for 
cancer treatment that involves the delivery of immune-modulating genes 
to the tumor site to induce an adaptive anti-tumor immune response in 
the host.  
This study was designed to develop a novel anti-cancer immunogene 
therapy effective against malignant melanoma in the C57BL/6 mouse 
model. A recombinant plasmid containing MART1, a human 
melanoma-specific tumor antigen, was used to induce an immune 
reaction against the mouse melan-A epitope in order to overcome the 
peripheral tolerance of the mouse to murine melan-A. In addition, mouse 
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granulocyte macrophage-colony stimulating factor (mGM-CSF) and 
short hairpin RNA against mouse transforming growth factor-β2 
(shmTGF-β2) genes were delivered together with MART1, because 
GM-CSF is known to be the most potent inducer of antitumor immunity, 
and TGF-β is known to be involved in tumor survival and host immune 
suppression. These genes were delivered to cancer cells by using an 
oncolytic adenovirus. A recombinant DNA expressing human MART1 
(MART1 plasmid) and a recombinant adenovirus expressing human 
MART1 were investigated for their potential effects on priming and 
boosting immune responses. 
First, the expression of MART1 was increased in MART1 
plasmid-transfected B16BL6 mouse melanoma cells in a dose-dependent 
manner in vitro. Notably, the cytotoxic activity of splenocytes isolated 
from MART1 plasmid-injected non-tumor-bearing mice was enhanced 
compared to those isolated from control plasmid-injected mice. 
Thus, recombinant oncolytic adenovirus expressing mGM-CSF and 
shmTGF-β2 were also investigated for their potential to stimulate the 
non-specific immune response and decrease the expression of signaling 
molecules involved in tumor cell survival and growth, respectively. To 
3 
 
 
 
this end, the effect of recombinant oncolytic adenovirus expressing both 
mGM-CSF and shmTGF-β2 (GT virus) was compared to that of the 
recombinant adenovirus expressing mGM-CSF only (G virus), following 
intratumoral injection of the virus into melanoma-bearing C57BL/6 mice. 
This investigation shows that administration of the G virus leads to 
delayed tumor growth compared to the empty viral control, while tumor 
growth in mice that received the GT virus was significantly decreased (P 
< 0.001) compared to both the control- and G virus-treated mice.  
Finally, an oncolytic adenovirus expressing MART1, mGM-CSF, and 
shmTGF-β2 (MGT virus) was constructed and administered to boost the 
immune response and cancer cell death. Administration of this virus 
induced a stronger and longer-lived immune response than that observed 
in the controls. Interestingly, none of the mice that received MART1 
plasmid pre-treatment in addition to MGT viral injection showed any 
signs of tumor growth and 100% were viable 43 days after tumor cell 
injection.  
This study investigates the anti-tumor effects of repeated MART1 
plasmid vaccination and immune stimulation/tumor cell lysis with an 
oncolytic adenovirus expressing MART1/mGM-CSF/shmTGF-β2. The 
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results presented herein highlight the function of these genes during 
tumorigenesis as well as the possible therapeutic options of this treatment 
strategy. Additional work is necessary to further evaluate the clinical 
application of this combination therapy to treat malignant melanoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
---------------------------------------------------------------------------------------------------------- 
Key words: malignant melanoma, immune therapy, tumor antigen, DNA vaccine, 
oncolytic adenovirus, MART1, GM-CSF, TGF-β2 
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I. INTRODUCTION 
 
Tumors, which arise from abnormal cell proliferation in a tissue, can be 
benign, pre-cancerous, or malignant. There are several methods for the 
treatment of tumors, such as surgery, chemotherapy and radiation therapy, but 
these therapies have limitations to treat malignant cancer; particularly for end 
stage cancer, metastatic cancer, and carry a high risk of relapse. In current 
medical practice, most cancer patients are treated with a combination of surgery, 
radiation, and/or chemotherapy. Although primary tumors in an early stage of 
malignancy can, in most cases, be efficiently treated with a combination of 
these standard therapies, efforts to prevent the metastatic spread of disseminated 
tumor cells are not often effective when treating patients in the late or end stage 
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of disease progression.  
The incidence of malignant melanoma is rapidly increasing worldwide 
1
 and 
is the fifth highest occurring cancer in the United States and United Kingdom 
2
. 
Although early primary melanomas can be cured surgically, once metastases 
develop, this type of cancer can rapidly become fatal. Furthermore, while 
therapeutic agents such as ipilimumab (a therapeutic agent that targets CTLA4) 
and vemurafenib (a therapeutic agent used against melanoma carrying a 
mutation in the BRAF gene), have been developed to fight malignant melanoma, 
these compounds have short treatment windows and low success rates 
3-6
. 
Therefore, new treatments are required in order to provide more options and, 
ideally, a better outcome for patients with late stage malignant melanoma. 
Recently, to overcome these limitations, new treatment modalities have 
been proposed, including gene therapy/immunotherapy. Cancer immunotherapy 
is intended to harness the reactivity of the host’s immune system to combat 
cancer. The main strategies of cancer immunotherapy aim to exploit the 
therapeutic potential of tumor-specific antibodies and cellular immune effector 
mechanisms. To date, adenovirus and retrovirus vectors have been the most 
predominantly used vectors for immunogene therapy; these are utilized in 23.3% 
and 19.7% of all immunotherapy treatments, respectively 
7
. Many features of 
the adenovirus make it well suited for gene delivery systems. For example, 
recombinant adenovirus can be grown to high titers and has a relatively high 
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capacity for transgene insertion, usually without the incorporation of viral DNA 
into the host cell genome 
8,9
. Moreover, the use of an oncolytic adenovirus in 
immunogene therapy will not damage normal cells, but is engineered to induce 
tumor-specific cell lysis 
8-10
. Initial attachment of the adenovirus virion particle 
to the cell surface occurs through binding of the fiber knob to the 
coxsackievirus B and adenovirus receptor (CAR) 
9
. Therefore, effective 
therapeutic gene delivery can be induced by using the adenoviral vector 
construct without any further engineering. Further, this vector can be used to 
transport various types of genes into the cell, without discrimination.  
 Notably, while immunogene therapy has shown promise in treating various 
types of cancer, only 0.1% of these therapies utilized in preclinical studies 
proceed into phase IV clinical trials 
7
. The success of immunogene therapies 
during a clinical trial is dependent on a number of factors, including whether the 
immune system was primed/boosted. For example, patients who have an 
immunological memory for the vaccine antigen would be expected to have a 
quick and strong immune response to the antigen 
11
. In contrast, patients with no 
immunological memory against the vaccine antigens will likely take more time 
to develop an effective antigen-specific immune response. Thus, several rounds 
of repeated vaccinations might be required to prime antigen-specific naive T 
cells to produce functional effector cells 
11
. It is also possible that immune 
priming/boosting using a tumor antigen could help to increase the immune 
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response of the patient during immunogene therapy. 
The injection site of the antigen, either intramuscularly or intradermally, has 
also been shown to be important in efficiently inducing a strong, long-lived 
immune response 
12
. While the intradermal route of administration appears to be 
the most efficient, there is some evidence suggesting that either route leads to 
antibody production and the activation of both major histocompatibility 
complex (MHC) class I-restricted antigen-specific cytotoxic T lymphocytes 
(CTL) and MHC class II-restricted CD4+ T cells secreting Th1-type cytokines 
13-15
. Intramuscular delivery of plasmid DNA vaccines has also been shown to 
lead to the expression of the encoded protein by a variety of cell types 
16,17
. 
Evidence suggests that professional antigen-presenting cells (APCs) may play a 
dominant role in the induction of immunity and that some APCs are directly 
transfected with plasmid DNA, causing them to rapidly migrate to the draining 
lymph nodes and initiate an immune response 
18,19
. Dendritic cells also play a 
role in cross-presenting antigen produced by transfected non-immune cells 
(such as muscle cells) 
20,21
. Both of these pathways are known to contribute to 
the activation of major histocompatibility complex (MHC)-matched CD8+ T 
cells, which then function to kill target cells and produce IFN-γ, an important 
activator of macrophage and inducer of class II MHC molecule expression 
22
. 
As a result, these pathways can stimulate innate and adaptive immunity. 
Furthermore, in terms of immunity induction, plasmid DNA immunization 
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has several potential advantages compared with traditional protein vaccination 
regardless of the injection site and has been shown to activate strong CTL and 
Th1 responses as well as resist antibody-mediated clearance, prolonging antigen 
expression 
13-15,23-25
. Currently, the primary types of anti-cancer genes that have 
been delivered to tumor sites via plasmid DNA/vector injection are antigen 
(20.5% of all immunotherapy treatments) and cytokine (18.4%) genes 
7
. While 
plasmid DNA vaccination with a single gene may evoke an immune response, 
single gene treatments targeting cancer have not shown high cure rates, likely 
because tumor cells have various immune evasion techniques 
26
. Thus, to induce 
a more effective anti-tumor effect, combination treatment with multiple 
therapeutic genes is likely necessary. In this study, I have focused on the use of 
GM-CSF (a cytokine), shRNA against TGF-β (an immunomodulatory protein), 
and MART1 (a human melanoma antigen) to determine their effectiveness 
when used in combination immunogene therapy to treat malignant melanoma. 
MART1 (melan-A), a human melanocyte lineage-specific protein, is 
expressed by 75–100% of melanomas, but is not detected in other cell or tumor 
types 
27
. Further, Butterfield et al. previously showed that vaccination with 
dendritic cells transduced with human MART1 protected against the murine 
counterpart of this melanocyte-lineage antigen 
28
. The basis of this cross-species 
protective response may related to the nearly 70% shared amino acid sequence 
28
. Therefore, administering MART1 plasmid as well as recombinant adenovirus 
10 
 
 
 
vector expressing MART1 would be expected to stimulate a stronger mouse 
melanoma antigen-specific immune response (essentially acting to prime/boost 
the system). 
Granulocyte macrophage-colony stimulating factor (GM-CSF), which is 
known to play an important role in the activation of immune cells, is expressed 
by a variety of cell types, including macrophage, T cells, mast cells, natural 
killer (NK) cells, endothelial cells, and fibroblasts 
29,30
. Because GM-CSF is a 
major factor involved in the immune response (non-specific) and is known to 
effectively induce a targeted immune response to melanoma cells 
31
, it is a good 
therapeutic candidate for immunogene treatment of this specific form of cancer. 
Transforming growth factor (TGF)-β is secreted in an autocrine and 
paracrine fashion by a variety of cell types in the tumor microenvironment, 
including the tumor cells, immune cells, and fibroblasts 
32
. There are three 
isoforms of TGF-β: TGF-β1 (expressed in epithelial, endothelial, hematopoietic, 
and connective tissue cells); TGF-β2 (expressed in epithelial and neuronal cells); 
and TGF-β3 (expressed primarily in mesenchymal cells) 33-35. TGF-β signals are 
known to have important roles in cell proliferation, differentiation, angiogenesis, 
and wound healing 
36,37
. In addition, TGF-β signaling helps cancer cells repress 
the immune response of certain cell types, including NK cells, dendritic cells, 
macrophage, and T cells, while also inducing the activation of regulatory T cells 
38
. Thus, reducing the expression of TGF-β in malignant melanoma would be 
11 
 
 
 
expected to inhibit the survival of tumor cells and induce activation of the 
immune system. 
In oncology, an inadequate immune response towards a tumor permits tumor 
growth 
39
. Therefore, a successful DNA vaccine for the treatment of tumors 
should essentially break the cancer cell’s established immune tolerance to the 
tumor antigen, inducing a strong, prolonged tumor-specific immune response. 
In Chapter III: RESULTS, I have outlined my findings concerning the use of 
mGM-CSF, shRNA against mTGF-β, and MART1 to treat malignant melanoma. 
With this investigation I have demonstrated that the combination of the MART1 
plasmid with an oncolytic adenovirus construct expressing MART1, mGM-CSF, 
and shmTGF-β2 have a pronounced anti-tumor effect on melanoma cells. (Fig 
1) 
 
 
12 
 
 
 
 
 
Figure 1. Schematic representation of the combination therapy developed in this 
study. To develop an improved cure for malignant melanoma, MART1 plasmid 
together with oncolytic adenovirus expressing MART1, mGM-CSF, and 
shmTGF-β2 were treated. 
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II. MATERIALS AND METHODS 
 
1. Construction of stable cell line expressing CAR and E1B55KDa 
After transfection with the pIRES-CAR/E1B55 plasmid expressing both 
CAR and E1B55 (one of the adenovirus proteins) proteins, B16BL6 cells were 
cultured in minimum essential medium (MEM, HyClone, Logan, UT, USA) 
with 10% fetal bovine serum (FBS), MEM vitamin solution (HyClone), and 0.5 
mg/mL of G418 (Calbiochem, La Jolla, CA, USA) as selection medium. The 
medium was changed every 2–3 days after transfection. Positive clones 
expressing both CAR and E1B55KDa protein were then selected and named 
B16BL6-CAR/E1B55. B16BL6-CAR/E1B55 cells were cultured in MEM with 
10% FBS, MEM vitamin solution, and 0.5 mg/mL of G418 and maintained in a 
37°C humidified atmosphere containing 5% CO2. 
 
2. Cell culture  
The B16BL6 (mouse melanoma) cell line was cultured in MEM with 10% 
FBS and MEM vitamin solution. NIH-3T3 (mouse embryo fibroblast), B16F10 
(mouse melanoma), LLC (Lewis lung carcinoma), A375 (human melanoma), 
and 293 (human embryonic kidney) cell lines were cultured in Dulbecco's 
modified Eagle's medium (DMEM, HyClone) with 10% FBS. SK-MEL-2 
(human melanoma), SK-MEL-3 (human melanoma), and SK-MEL-28 (human 
14 
 
 
 
melanoma) were cultured in Roswell Park Memorial Institute (RPMI)-1640 
(HyClone) with 10% FBS. Cells were maintained in a 37°C humidified 
atmosphere containing 5% CO2. 
 
3. Construction of GFP expressing replication-defective adenoviral vector 
The EGFP originated from pEGFP-N1 (Clontech Laboratories, Mountain 
View, CA, USA) and was cloned into the pCA14 vector by digestion using the 
restriction enzymes XhoI and XbaI. After linearization by XmnI digestion, it 
was co-transformed into Escherichia coli BJ5183 with the Bsp119I-digested 
adenoviral vector (dl324-BstBI: adenovirus vector with an E1 and E3 region 
deletion) for homologous recombination.  
To verify the homologous recombination, the plasmid DNA purified from 
the overnight E. coli culture was digested with HindIII and the digestion 
pattern was analyzed. The homologous recombinant adenoviral plasmid DNA 
was digested with PacI and transfected into 293 cells to generate 
replication-deficient adenovirus. 
 
4. Construction of oncolytic adenoviral vectors 
A. E3 region – shuttle vector cloning and homologous recombination 
For the expression of siRNA targeting mTGF-β1 or mTGF-β2, the short 
hairpin RNA (shRNA) construct was cloned into pSP72ΔE3-U6 vector by 
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digestion with BamHI and HindIII. These vectors named 
pSP72ΔE3-U6-shmTGF-β1 and pSP72ΔE3-U6-shmTGF-β2 (E3 shuttle 
vector). The U6 promoter of pSP72ΔE3-U6-shmTGFβ2 plasmid was replaced 
with H1 promoter through digestion with SphI and BamHI. And then U6 
promoter-shmTGFβ1-SV40 construct from pSP72ΔE3-U6-shmTGFβ1 
(SphI-blunt-KpnI) was cloned into the pSP72ΔE3-H1-shmTGFβ2 plasmid 
(HindIII-blunt-KpnI). This recombinant E3 shuttle vector was called 
pSP72ΔE3-H1-shmTGFβ2-U6-shmTGFβ1. These recombinant shuttle vectors 
were linearized by XmnI digestion and co-transformed into E. coli BJ5183 
together with the SpeI-digested adenoviral vector (dl324-BstBI) for 
homologous recombination. The E1 shuttle vector was then linearized by PmeI 
digestion and co-transformed into E. coli BJ5183 with the BstBI-digested 
dl324-BstBI-ΔE3-U6-shmTGFβ1, dl324-BstBI-ΔE3-H1-shmTGFβ2 or 
dl324-BstBI-ΔE3-H1-shmTGFβ2-U6-shmTGFβ1 for homologous 
recombination. 
 
B. E1 region – shuttle vector cloning and homologous recombination 
For the construction of oncolytic adenoviral E1 shuttle vector, inverted 
terminal repeats (ITR)-packaging signal-mouse survivin promoter-E1A-BGH 
polyA construct from pBSK[3484]
40
 was cloned into HindⅢ/EcoRI digested 
pVAX1 and this vector was called pVAX1-3484-ΔE1B. And then the E1R gene 
16 
 
 
 
of adenovirus from pCA14 (StuI-blunt-EcoRI) was cloned into the 
pVAX1-3484-ΔE1B vector (ApaI-blunt-EcoRI). This recombinant vector was 
named pVAX1-3484--ΔE1B-E1R. The mouse survivin promoter was replaced 
with CMV promoter, through digestion with KpnI and XhoI. pcDNA3.1-Hygro
+
 
was used as a template for PCR amplification of the CMV promoter, with the 
sense primer, 5'-CGGGGTACCGATGTACGGGCCAGAT-3', and the anti-
sense primer, 5'-CCGCTCGAGAATTTCGATAAGCCAG-3'. Following 
digestion of the PCR product of the CMV promoter with KpnI/XhoI, it was 
inserted into KpnI/XhoI-digested pVAX1-3484-ΔE1B-E1R. This recombinant 
oncolytic E1 shuttle vector was called pVAX1-3484-CMV-ΔE1B.  
For the expression of MART1 (pVAX1-MART1, a gift from Dr. Butterfield, 
University of Pittsburgh, PA, USA) and mGM-CSF (Invivogen, San Diego, 
CA, USA), genes were cloned into the pIRES vector using NheI/MluI and 
XbaI/NotI restriction sites. The [CMVp-MART1-IRES], [CMVp-IRES 
-mGM-CSF], and [CMVp-MART1-IRES-mGM-CSF] constructs were then 
cloned into BglII/SalI digested pVAX1-3484-CMV-ΔE1B vector and this 
plasmid was named as pVAX1-3484-CMV-ΔE1B-MART1, pVAX1-3484 
-CMV-ΔE1B-mGM-CSF, and pVAX1-3484-CMV-ΔE1B-MART1-IRES- 
mGM-CSF. These vectors are oncolytic E1 shuttle vectors. The E1 shuttle 
vector was then linearized by PmeI digestion and co-transformed into E. coli 
BJ5183 with the BstBI-digested dl324-BstBI or dl324-BstBI-ΔE3-H1 
17 
 
 
 
-shmTGF-β2 for homologous recombination. 
 
5. Oncolytic recombinant adenoviruses 
C virus: 
Ad3484-CMVp-ΔE1B, control virus 
T1 virus: 
Ad3484-CMVp-ΔE1B-ΔE3-U6-shmTGF-β1, 
virus expressing a shRNA against mTGF-β1 
T2 virus: 
Ad3484-CMVp-ΔE1B-ΔE3-H1-shmTGF-β2,  
virus expressing a shRNA against mTGF-β2 
G virus:  
Ad3484-CMVp-ΔE1B-CMVp-mGM-CSF,  
virus expressing mGM-CSF 
GT virus:  
Ad3484-CMVp-ΔE1B-CMVp-mGM-CSF-ΔE3-H1-shmTGF-β2, 
virus expressing mGM-CSF and a shRNA against mTGF-β2 
M virus:  
Ad3484-CMVp-ΔE1B-CMVp-MART1,  
Virus expressing human MART1 
MGT virus:  
18 
 
 
 
Ad3484-CMVp-ΔE1B-CMVp-MART1-IRES-mGM-CSF-ΔE3-H1-shmTGF-β2
virus expressing human MART1, mGM-CSF, and a shRNA against mTGF-β2 
 
6. Flow cytometric analysis 
After B16BL6-CAR/E1B55 cells were infected with recombinant 
adenovirus for two days, infected cells were trypsinized and washed twice with 
ice-cold phosphate buffer saline (PBS). Cells were then incubated with an 
anti-MART1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 
h at 4°C. After two washes with ice-cold PBS, cells were incubated with an 
APC-conjugated anti-mouse IgG (BD Biosciences, Lincoln Park, NJ, USA) 
antibody in the dark for 45 min at 4°C and then washed twice with ice-cold 
PBS. A mouse IgG fluorescence control (BD Biosciences) antibody was used 
as a negative control. Finally, cells were resuspended in PBS and analyzed 
using a FACS Calibur flow cytometer (BD Biosciences). 
 
7. Cytopathic effect assay 
To evaluate the cytopathic effect (CPE) of several tumor-selective 
replication-competent adenoviruses, cells were first plated at about 80% 
confluence into the well of a 48-well plate. They were infected with various 
multiplicities of infection (MOIs) of replication-competent adenovirus. After 24 
h of infection, cells were monitored daily by microscopy. When cells exhibited 
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lysis at the lowest MOI, the remaining cells on the plate were fixed with 4% 
paraformaldehyde and stained with 0.05% crystal violet. 
 
8. Murine spleen cell preparation 
The spleen was extracted from C57BL/6 mice one week after last injection 
of pVAX1-MART1 (a plasmid expressing MART1) or pVAX1 (control plasmid) 
DNA or 6 days after last injection of adenovirus. After extraction, the spleen 
and 1 mL of PBS were directly placed into the cell strainer in the petri dish, the 
spleen was mashed by using the black rubber of a syringe and splenocytes were 
released into the petri dish. The homogenized cell suspension was then washed 
twice with PBS. The splenocytes were resuspended in 4 mL of PBS per spleen 
and the appropriate amount of ammonium chloride lysing reagent (BD 
Biosciences) was added. The cells were incubated for 15 min in the dark at 
room temperature. Cells were washed twice with PBS and resuspended in the 
desired medium (RPMI-1640). 
 
9. Lactate dehydrogenase assay (LDH assay) 
The cytotoxic activity of splenocytes against tumor cells was assessed by 
LDH assay using the Non-radioactive cytotoxicity assay kit (Promega 
Corporation, Madison, WI, USA). Cancer cells were incubated for 12 h in 
48-well plate at 37°C under a humidified atmosphere of 5% CO2 in air and then 
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co-cultured with splenocytes isolated from C57BL/6 mice for 4 h. For the LDH 
positive control, 45 μL of lysis solution (10) was added to all wells to lyse the 
cells and the cells were incubated for 45 min. After 45 min of incubation, the 
plate was centrifuged at 250 × g for 4 min. Fifty microliters of supernatant from 
all wells were transferred to a fresh 96-well flat-bottom plate. Fifty microliters 
of reconstituted substrate mix were added to each well and the plate was then 
incubated for 30 min at room temperature in the dark. After 30 min, 50 μL of 
stop solution was added to each well and the absorbance was recorded at 490 
nm within 1 h using a microplate reader (Molecular Devices Corporation, 
Sunnyvale, CA, USA). The percentage of splenocyte cytotoxicity was 
calculated using the following formula: 
% Cytotoxicity = {(experimental value - effector control value - negative 
control value) / (positive control value - negative control value)}*100.  
 
10. Western blot analysis 
Two days after transfection with the MART1 plasmid or infection with a 
recombinant adenovirus, B16BL6-CAR/E1B55 cells were lysed with 1 Laemmli 
lysis buffer (62.5 mM Tris, pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol, 
0.002% bromophenol blue) and the protein concentration was determined by using 
the BCA Protein Assay Kit (Thermo Scientific, Fremont, CA, USA). Protein 
samples were then separated by sodium dodecyl sulfate-polyacrylamide gel 
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electrophoresis and the gels were electrotransferred onto a polyvinylidene 
difluoride membrane (Millipore, Billerica, MA, USA). Immunodetection was 
performed with anti-Src (Cell Signaling Technology, Beverly, MA, USA), 
anti-phospho Src (pSrc) (Cell Signaling), anti-STAT3 (Cell Signaling), 
anti-phospho STAT3 (pSTAT3) (Cell Signaling), anti-p65 (Cell Signaling), 
anti-phospho p65 (pp65) (Cell Signaling), anti-β-catenin (Cell Signaling), 
anti-N-cadherin (Cell Signaling), anti-actin (Santa Cruz Biotechnology), 
anti-melanA (Santa Cruz Biotechnology), and anti-MART1 (Santa Cruz 
Biotechnology) antibodies by using a chemiluminescent and fluorescent image 
analysis system (Syngene, Cambridge, UK). 
 
11. Real-time polymerase chain reaction 
After 2 days of infection with the recombinant adenovirus, 
B16BL6-CAR/E1B55 cells were lysed with TRIzol reagent (Life Technologies, 
Carlsbad, CA, USA) and the total RNA was isolated by using chloroform. The 
RNA concentration was determined by using the Nanodrop 2000 (Thermo 
Scientific). RT-PCR was performed using the Power SYBR Green RNA-to-CT 
1-Step Kit (Life Technologies). The reaction mixture contained the reverse 
transcriptase enzyme mix, reverse transcription PCR mix, forward primer, reverse 
primer, RNA template, and nuclease-free water. Mouse TGF-β1 cDNA was 
amplified using the forward primer: 5-TTGCTTCAGCTCCACAGAGA-3 and 
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the reverse primer: 5-TGGTTGTAGAGGGCAAGGAC-3. Mouse TGF-β2 
cDNA was amplified using the forward primer: 5-GTGAATGGCTCTCCTTC 
GAC-3 and the reverse primer: 5-CCTCGAGCTCTTCGCTTTTA-3. Mouse 
TGF-β3 cDNA was amplified using the forward primer: 5-CTATCAGGTCCT 
GGCACTTT-3 and the reverse primer: 5-GGCAGATTCTTGCCACCTAT-3. 
Mouse β-actin was amplified using the forward primer: 5-GGCTGTATTCCC 
CTCCATCG-3 and the reverse primer: 5-CCAGTTGGTAACAATGCCATG 
T-3. 
 
12. Enzyme-linked immunosorbent assay (ELISA) 
B16BL6-CAR/E1B55 cells were plated onto six-well plates at 2 × 10
5
 
cells/well and then infected with adenoviruses (C virus, G virus, T virus, GT 
virus, or MGT virus) at an MOI of 50. Forty-eight hours after infection, the 
supernatants were harvested. mGM-CSF and mTGF-β2 level of expression was 
determined by using ELISAs according to the manufacturer’s instructions 
(mGM-CSF ELISA kit and mTGF-β2 ELISA kit: R&D systems, Minneapolis, 
MN). 
 
13. Animal study  
Tumors were implanted subcutaneously in the abdomen of C57BL/6 mice by 
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injecting B16BL6-CAR/E1B55 murine melanoma cells (7  105) in 100 μL of 
Hank’s balanced salt solution (HBSS; Gibco BRL, Carlsbad, CA, USA).  
In the first experiment, when tumors reached a range of 70–100 mm3, 
animals were randomized into 4 groups of 5 animals (PBS, 
Ad3484-CMVp-ΔE1B, Ad3484-CMVp-ΔE1B-CMVp-mGM-CSF, and Ad3484 
-CMVp-ΔE1B-CMVp-mGM-CSF-ΔE3-H1-shmTGF-β2). Adenoviruses or PBS 
were administered intratumorally (virus; 1  109 PFU (PFU; plaque-forming 
unit) per tumor in 50μL of PBS) on day 1, 3, and 5. 
In the second experiment, 4 days after tumor implantation, C57BL/6 mice 
were injected intramuscularly in the rear quadriceps with 50 μg of 
pVAX1-MART1 (M) encoding human MART1 in a total volume of 50 μL 
saline using a 29-gauge needle. When tumors reached a range of 70–100 mm3, 
animals were randomized into 4 groups of 5 animals (M+PBS, 
M+Ad3484-CMVp-ΔE1B, M+Ad3484-CMVp-ΔE1B-CMVp-MART1, and M+ 
Ad3484-CMVp-ΔE1B-CMVp-MART1-IRES-mGM-CSF-ΔE3-H1-shmTGF-β2) 
and treatment was initiated. The first day of treatment was designated as day 1. 
Adenoviruses or PBS were administered intratumorally (1  109 PFU per tumor 
in 50 μL of PBS) on days 1, 3, and 5.  
In the third experiment, C57BL/6 mice were injected intramuscularly in the 
rear quadriceps with 50 μg of pVAX1-MART1 in a total volume of 50 μL 
saline using a 29-gauge needle. The plasmid was injected 3 and 7 days prior to 
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tumor injection and 1 day after tumor injection. On day -7, tumors were 
implanted subcutaneously as described above. When tumors reached a range of 
70–100 mm3, animals were randomized into 4 groups of 5 animals (M+PBS, 
M+Ad3484-CMVp-ΔE1B, M+Ad-3484-CMVp-ΔE1B-CMVp-MART1, and M 
+Ad-3484-CMVp-ΔE1B-CMVp-MART1-IRES-mGM-CSF-ΔE3-H1-shmTGF-
β2) and treatment was initiated. The first day of treatment was designated as 
day 1. Adenoviruses or PBS were administered intratumorally (1  109 PFU per 
tumor in 50 μL of PBS) on days 1, 3, and 5. 
Regression of tumor growth was assessed by taking measurements of the 
length (L) and width (W) of the tumor. Tumor volume was calculated using the 
following formula: volume = 0.52 * L * W
2
. 
 
14. Immunohistochemistry (IHC) 
Immunohistochemistry studies were performed on paraffin-embedded tumor 
tissues using anti-CD4 (Novus Biologicals, Littleton, CO, USA), anti-NK1.1 
(Novus Biologicals), anti-CD8 (Santa Cruz Biotechnology), anti-CD11b+c 
(Thermo Scientific), and anti-adenovirus type 5 (Novus Biologicals) antibodies to 
determine the expression of these proteins in the tumor tissue. The tumor tissue 
slides were deparaffinized by incubation in xylene for 10 min and rehydrated 
serially in alcohol (100%, 90%, and 70%). Endogenous peroxidase was blocked by 
incubation with 3% H2O2 for 15 min at room temperature and antigen retrieval was 
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achieved by incubating the slides in citrate buffer for 10 min in a steamer. For 
permeabilization, the slides were incubated in PBS containing 0.5% Triton X-100 
for 30 min and then washed three times with PBS. To reduce nonspecific 
background staining due to endogenous peroxidases, the slides were incubated 
with a hydrogen peroxide block (Thermo Scientific) for 10 min. After washing, an 
ultra V block (Thermo Scientific) was applied to the slides for 5 min at room 
temperature to further block nonspecific background staining. The slides were 
incubated with an anti-CD4 antibody (1:200 dilution), an anti-CD8 antibody 
(1:500), anti-NK1.1 antibody (1:500), anti-CD11b+c antibody (1:500), and an 
anti-Ad5 antibody (1:800 dilution) for 12 h at 4°C and further with a horseradish 
peroxidase polymer (Thermo Scientific) for 15 min at room temperature. To detect 
protein expression, the tissue sections were stained with diaminobenzidine 
tetrahydrochloride and minimally counterstained with hematoxylin (for 
visualization of antigen-antibody complexes). Sections were mounted under a 
coverslip using an mounting solution (Shandon Synthetic Mountant (Thermo 
Scientific) + xylene = 1:1). 
 
15. Preparation of B16BL6 cell lysate 
After removing the culture medium, B16BL6 cells were washed with PBS twice. 
Cells were then detached with a rubber policeman in 1 mL of cold PBS and 
transferred into a 1.5 ml tube. After centrifugation at 3000 rpm for 15 min, the 
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supernatant was removed. The cell pellet was resuspended with 1 mL of cold 
radioimmunoprecipitation assay buffer (RIPA) buffer (Thermo Scientific) with 
protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA), and incubated on ice for 
30 min with vortexing every 10 min. After centrifugation at 14000 × g for 15 min 
at 4°C, the supernatant, which contains the total protein, was transferred in a new 
tube and stored at  80°C. 
 
16. IFN-γ enzyme-linked immune spot (ELISPOT) assay 
To assess the population of antigen-specific cytokine-producing cells, IFN-γ 
ELISPOT assay was performed. Six days after the last adenovirus injection, the 
spleens were collected aseptically from mice bearing a B16BL6 tumor and 
unicellular splenocytes were prepared as described above. Prepared spleen cells 
were stimulated with B16BL6 cell lysate for 24 h in the culture medium. IFN-γ 
ELISPOT assay was then carried out according to the manufacturer’s 
specifications (IFN-γ ELISPOT kit: R&D Systems). The colored spots, 
representing IFN-γ-producing cells, were counted with a KS-ELISpot 
(Zeiss-Kontron, Jena, Germany) and confirmed by the computer-based 
Immunospot system (AID Elispot Reader System, Version 3.4; Autoimmun 
Diagnostika GmbH, Strassberg, Germany). 
 
17. Statistical analysis 
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Data were expressed as mean ± standard error (SE). Statistical comparison was 
made using SigmaPlot 8.0 (Systat Software Inc, San Jose, CA, USA). P values 
less than 0.05 were considered statistically significant (*, P < 0.05; **, P < 
0.01;***, P < 0.001). 
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III. RESULTS 
 
1. Establishment of a cell line for adenovirus infection and replication 
Most murine cancer cell lines have a lower adenovirus infection efficiency 
compared to human cancer cells, as mouse cells do not express CAR. In 
addition, the replication rate of adenovirus is very low and this limits the 
effectiveness of the oncolytic adenovirus in killing mouse cancer cells. To 
overcome these limitations, the B16BL6-CAR/E1B55 mouse melanoma cell 
line was developed, which expresses both the CAR and adenoviral E1B55 
genes. Notably, this transgenic cell line showed enhanced infectivity by 
adenovirus (Fig 2A). The replication-dependent cytotoxic effect of adenovirus 
in the B16BL6-CAR/E1B55 cells was also quantitatively assessed using an in 
vitro CPE assay. This analysis indicates that replication of the oncolytic 
adenovirus was induced in the B16BL6-CAR/E1B55 cells in a multiplicity of 
infection (MOI) value-dependent manner (Fig 2B, C). 
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(B)                                                (C) 
         
 
Figure 2. Infectivity of adenovirus in B16BL6-CAR/E1B55 cell line. (A) A375 
(human melanoma cell line), B16BL6 (mouse melanoma cell line), and 
B16BL6-CAR/E1B55 were infected with adenovirus-GFP at a multiplicity of 
infection (MOI) of 50. After 48 h, GFP expression was detected by fluorescence 
microscopy (fluorescence microscope; Olympus). (B) The 
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B16BL6-CAR/E1B55 cell line was infected with the adenovirus at various 
MOIs. (C) To compare the oncolytic activity induced by Ad3484-CMVp-ΔE1B, 
cancer and NIH-3T3 cells were infected with virus at an MOI of 1 to 20. When 
293 cells infected with the viruse at an MOI of 1 exhibited complete cell lysis, 
all the remaining cells on the plate were fixed with 4% paraformaldehyde and 
stained with 0.5% crystal violet. 
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2. Induction of an mouse melanoma antigen-specific immune response 
using human MART1 in mouse melanoma cells 
Butterfield et al. (1998) previously showed that dendritic cells that were 
genetically modified to express the human MART1 antigen generated a potent 
melan-A-specific immune response in BL6 melanoma model 
28
. These results 
imply that stimulation of MART1 could potentially induce a melan-A-specific 
immune response in our mouse melanoma model. 
Human melanoma cell lines (including SK-MEL-2, SK-MEL-3, and 
SK-MEL-28) express MART1, and the murine melan-A, which shares 68.8% 
sequence similarity with the human form, is expressed in the mouse melanoma 
cell lines B16BL6 and B16F10, but not in NIH-3T3 cells (Fig 3A). 
Accordingly, I chose to use MART1 as a target for immune priming/boosting 
immunotherapy for the treatment of malignant melanoma. Further, a 
recombinant pVAX1-MART1 plasmid was used to express the protein, and 
empty pVAX1 was used as a control plasmid. Following transfection into 
murine melanoma cells, the expression of MART1 was observed to increase in 
the MART1 plasmid-transfected cells in a dose-dependent manner (Fig 3B).  
To induce immune activation, 50 μg of MART1 plasmid in a total volume 
of 50 μl saline was injected intramuscularly into the rear quadriceps of C57BL/6 
mice. This injection site was chosen because muscle cells injected with plasmid 
DNA have been shown to produce large amounts of the encoded protein 
16,17
. 
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Notably, injections of MART1 plasmid were administered three times, 
separated by a one-week interval between injections. One week after the final 
injection, mice were killed and their spleens were removed. To determine the 
effect of MART1 immune priming, splenocytes were isolated, co-cultured with 
B16BL6 melanoma cells, and the spontaneous release of LDH was measured. 
Figure 3C shows the cytotoxic activity of the splenocytes isolated from the 
MART1 plasmid-injected mice, which was effectively enhanced compared to 
that of the splenocytes isolated from the control plasmid-injected mice. This 
enhanced cytotoxic activity of the splenocytes also appeared to be dependent on 
the ratio of effector cells (splenocytes) and the target cells (B16BL6 cells). 
Further, activation of the immune system induced by MART1 plasmid 
treatment was not observed in the LLC cell line, a mouse lung cancer cell line 
that does not express melan-A. These data indicate that the injection of human 
MART1 plasmid can prime mouse melan-A-specific immunity by inducing the 
development of an immune cell population that is cross-reactive to both human 
MART1 and mouse melan-A. Based on these findings, I conclude that an 
effective and specific anti-tumor immune response could be induced in the 
B16BL6 mouse melanoma model by administering MART1 plasmid. 
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(A)  
    
(B) 
 
(C) 
 
Figure 3. Mouse melanoma antigen-specific immune priming effect of human 
MART1 plasmid. (A) MART1 and MelanA expression were detected in various 
human and mouse cells by western blot. Actin was used as a loading control. (B) 
MART1 expression level was assessed in B16BL6 cells after transfection with 
pVAX1 or pVAX-MART1. (C) Splenocytes isolated from mice injected with 
control plasmid or MART1 plasmid were co-cultured with B16BL6 or LLC 
cells for 4 h. The cytotoxicity of splenocytes was then determined by LDH 
assay. 
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3. Downregulation of TGF-β in melanoma cells 
Almost all human tumors overexpress TGF-β, which contributes to the 
induction of tumor cell invasion and metastasis 
41
. Another major role of 
TGF-β produced by tumors is to block the immune response 42. This local 
TGF-β-induced immunosuppressive environment has been shown to be the 
major obstacle to immunogene therapy using cytokines 
43
. Accordingly, in this 
study shRNA against TGF-β was used as a therapeutic agent. 
It has been known that TGF-β1 and TGF-β2 are highly expressed in 
melanoma, whereas TGF-β3 is rarely expressed. To decrease the expression of 
TGF-β1 and TGF-β2 protein, recombinant adenoviruses were constructed 
containing the shRNAs TGF-β1-sh10 and TGF-β2-sh3 (Fig 4A) individually or 
together (Fig 4B). Two different promoters (U6 promoter and H1 promoter) 
were used to prevent the formation of secondary DNA structure. 
The downregulation of the mTGF-β transcripts following 
B16BL6-CAR/E1B55 cell infection with adenovirus expressing shRNA against 
mTGF-β1, mTGF-β2, or both was confirmed by real time PCR. As shown in 
Figure 5A, the infecting the cells with the shmTGF-β1 virus decreased the 
expression of mTGF-β1 mRNA level but not mTGF-β2. Similarly, treatment 
with shmTGF-β2 virus decreased the mTGF-β2 mRNA level by more than 50% 
compared to the controls. Furthermore, the endogenous cellular level of TGF-β 
mRNA was significantly decreased when the cells were infected with 
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adenovirus expressing shRNAs targeting both TGF-β1 and TGF-β2. 
And then the expression levels of various endogenous signaling molecules 
were decreased by treatment with the shmTGF-β adenovirus. Figure 5B shows 
that the down-regulation of TGF-β isotypes induced changes in the expression 
of signaling molecules involved in cell growth, survival, or metastasis. 
 The expression of signaling molecules were decreased in 
shmTGF-β2-expressing adenovirus infected cells. But when both the TGF-β1 
and TGF-β2 transcripts were silenced by infection with virus comprising both 
of the shmTGF-β1 and shmTGF-β2 DNA sequences, the effects on the 
expression of signaling molecules were lessened compared with those observed 
following transduction with the virus containing the shmTGF-β2 DNA 
sequence only. These results suggest that the downregulation of TGF-β2 is the 
primary TGF-β signaling molecule necessary to inhibit the growth and survival 
of mouse melanoma tumors. We, therefore, chose to focus on using the 
shmTGF-β2 construct for further investigations. 
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Figure 4. Schematic representation of shmTGF-β expressing adenovirus vectors. 
After selection of TGF-β1-sh10 and TGF-β2-sh3 to induce the down-regulation 
of mTGF-β1 and mTGF-β2 mRNA level (A), oncolytic adenoviruses were 
developed (B). Ad3484-CMVp-ΔE1B is a replication-competent adenovirus 
used as a control virus and contains the E1A gene controlled by the CMV 
promoter, but lacks the E1B gene. Ad3484-CMVp-ΔE1B-ΔE3-U6-shmTGF-β1 
(T1) and Ad3484-CMVp-ΔE1B-ΔE3-H1-shmTGF-β2 (T2) are composed of the 
shmTGF-β1 or shmTGF-β2 genes in the E3 region of Ad3484-CMVp-ΔE1B, 
respectively. Ad3484-CMVp-ΔE1B-ΔE3-H1-shmTGF-β2-U6-shmTGF-β1 (T1 
+ T2) is composed of the shmTGF-β1 and shmTGF-β2 genes in the E3 region 
of Ad3484-CMVp-ΔE1B. 
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Figure 5. TGF-β transcriptional level and change in cell-signaling molecules by 
shmTGF-β1 and shmTGF-β2 expressing adenoviruses. (A) Relative expression 
level of mTGF-β1 and mTGF-β2 mRNA. C, T1, T2, or T1+T2 virus was 
infected into B16BL6-CAR/E1B55 cells at an MOI of 100. The knockdown 
efficiency of these viruses was measured by quantitative real-time polymerase 
chain reaction amplifying mTGF-β1 and mTGF-β2. (B) B16BL6-CAR/E1B55 
cells were infected with C, T1, T2, or T1+T2 virus of 100 MOI. After two days, 
the endogenous expression levels of signaling molecules were detected by 
western blot assay. Actin was used as a loading control. 
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4. Construction and transfection of recombinant adenovirus expressing 
both mGM-CSF and shmTGF-β2 
GM-CSF is a potent inducer of anti-tumor immunity that has been used as a 
part of various strategies to induce anti-tumor effects via tumor-reactive 
cytotoxic CD8+ T-lymphocytes, NK cells, and dendritic cells 
44-46
. However, 
the systemic use of recombinant GM-CSF is compromised by side effects and 
the induction of potentially harmful myeloid-derived suppressor cells. 
Additionally, the efficacy of systemic recombinant GM-CSF treatment may 
remain limited as only a low local concentration of GM-CSF is found in tumors 
47
. Therefore, local GM-CSF production by cancer cells could ensure a 
sufficient local concentration while minimizing systemic exposure. Thus, 
adenovirus transport and infection is an appealing molecule/technique for local 
delivery of GM-CSF to tumors, and the effects of this gene could possibly be 
further compounded by utilizing oncolytic adenoviruses.  
Utilizing the results from my previous investigation concerning the role of 
mTGF-β2, I chose to examine the effects of combination treatment with 
mGM-CSF and shmTGF-β2. To develop the mGM-CSF-expressing 
recombinant oncolytic adenovirus, the mGM-CSF gene was inserted into the E1 
region of the virus and the resulting construct was named 
Ad3484-CMVp-ΔE1B-CMVp-mGM-CSF (G virus). The oncolytic adenovirus 
expressing both mGM-CSF and shmTGF-β2 as well was named 
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Ad3484-CMVp-ΔE1B-CMVp-mGM-CSF-ΔE3-H1-shmTGF-β2 (GT virus) 
(Fig 6A). To examine the protein expression level of mGM-CSF and the mRNA 
expression of mTGF-β2, B16BL6-CAR/E1B55 cells were infected with virus at 
an MOI of 50. Two days after infection, I observed a significant increase in 
mGM-CSF protein (Fig 6B) and a significant reduction of mTGF-β2 mRNA 
(Fig 6C). The oncolytic ability of these replication-competent adenoviruses was 
also analyzed using an in vitro CPE assay of various cell lines (293, 
B16BL6-CAR/E1B55, NIH-3T3) after cells were infected with control (C), G, 
or GT virus at different MOIs. As shown in Figure 6D, all 
replication-competent adenoviruses induced an increase in CPE as the MOI 
increased in the B16BL6-CAR/E1B55 melanoma cancer cell line, but not in 
NIH-3T3. 
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Figure 6. mGM-CSF and shmTGF-β2 expressing recombinant adenoviruses. (A) 
Schematic representation of adenovirus vectors expressing mGM-CSF and 
shmTGF-β2. Ad3484-CMVp-ΔE1B-CMVp-mGM-CSF (G) is composed of the 
mGM-CSF gene in the E1 region and Ad3484-CMVp-ΔE1B-CMVp 
-mGM-CSF-ΔE3-H1-shmTGF-β2 (GT) is composed of the shmTGF-β2 gene in 
the E3 region of Ad3484-CMVp-ΔE1B-CMVp-mGM-CSF. Two days after 
infection, mGM-CSF expression level was measured in the culture supernatants 
by ELISA (B) and mTGF-β mRNA was estimated by real-time-PCR (C). The 
oncolytic activity of these viruses was analyzed by in vitro cytopathic effect 
(CPE) assay. Cells were infected with each virus at an MOI of 0.1 to 50. To 
examine the level of mGM-CSF and mTGF-β2 mRNA expression, 
B16BL6-CAR/E1B55 cells were infected with virus at a MOI of 50 (D). 
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5. Ex vivo and in vivo testing of combination treatment with shmTGF-β2 
and mGM-CSF 
To demonstrate that an enhanced anti-cancer immune response was induced 
by recombinant adenovirus expressing both mGM-CSF and shmTGF-β2, ex 
vivo and in vivo tests were performed. B16BL6-CAR/E1B55 cells infected with 
virus at an MOI of 50 were incubated for 4 hours with splenocytes isolated from 
C57BL/6 mice and the cytotoxic activity was then measured with an LDH assay. 
Notably, the GT virus-infected cells appeared to enhance the anti-tumor activity 
of the splenocytes compared to the cells infected with mGM-CSF virus or 
shmTGF-β2 virus alone (Fig 7A). 
To determine whether the same effects were induced in an animal model of 
melanoma, C57BL/6 mice were subcutaneously injected with 
B16BL6-CAR/E1B55 murine melanoma cells in the abdomen. When tumors 
reached 70–100 mm3 in size, mice were intratumorally injected with PBS, the 
empty vector (C virus), G virus, or GT virus on days 1, 3, and 5. As shown in 
Figure 7B, control tumors that received PBS showed robust growth. In marked 
contrast, C, G, GT virus-treated tumors reached average volumes of 1719.1 ± 
180.1 mm
3
, 1342.5 ± 254.1 mm
3
, and 810.3 ± 112.5 mm
3
, respectively, by 9 
days. By day 20, the C, G, or GT virus-treated tumors reached average volumes 
of 10746.9 ± 663.9 mm
3
, 5360.6 ± 2115.0 mm
3
, and 4443.8 ± 925.7 mm
3
, 
respectively. These results indicate that the G virus can delay tumor growth 
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compared to the control virus and that combined treatment with mGM-CSF 
together with shmTGF-β2 resulted in a delayed growth rate of tumors compared 
with those of the mice treated with mGM-CSF alone. This enhanced anti-tumor 
effect for the combination treatment can be attributed to the simultaneous 
stimulation of a non-specific mGM-CSF-induced immune reaction and a 
decrease in mTGF-β2 expression. In addition, the tumor growth inhibition 
resulting from the decreased expression of mTGF-β2 mRNA had a positive 
effect on the anti-tumor response in the animal model. 
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Figure 7. The anti-tumor effect of adenoviruses expressing mGM-CSF with 
shmTGF-β2. The anti-tumor effect of G, T, or GT virus was confirmed by ex 
vivo (A) and in vivo (B) experiments. (A) B16BL6-CAR/E1B55 cells infected 
with each virus at an MOI of 50 were incubated for 4 h with splenocytes 
isolated from C57BL/6 mice. The splenocyte cytotoxic activity was measured 
by an LDH assay. (B) C57BL/6 tumor-bearing mice were treated with 
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intratumoral injections of 1 × 10
9
 PFU/50 μL of adenoviruses on days 1, 3, and 
5. Tumor volume was monitored and recorded every 2 days until the end of the 
study. Values represent the mean ± SE (5 animals per group). 
 
 
 
6. Construction of a recombinant adenovirus expressing MART1, 
mGM-CSF, and shmTGF-β2 
To induce a stronger and long-term immune response, a recombinant 
pVAX1-MART1 plasmid and a recombinant oncolytic adenovirus expressing 
MART1, mGM-CSF, and shmTGF-β2 were constructed. Ad3484-CMVp- 
ΔE1B-MART1 (M virus) was constructed, with the objective of 
priming/boosting an antigen-specific immune response in the mouse melanoma 
cells. Ad3484-CMVp-ΔE1B-MART1-IRES-mGM-CSF-ΔE3-H1-shmTGF-β2 
(MGT virus) was constructed with the aim of further enhancing the mouse 
melanoma antigen-specific immune response, general immune response, and 
suppression of cancer cell growth. MART1 and mGM-CSF, harbored in an 
internal ribosome entry site (IRES) expression cassette, were inserted into the 
E1 region of the adenovirus genome, while shmTGF-β2 was inserted into the 
E3 region (Fig 8A). The oncolytic activity of these recombinant adenoviruses 
was verified by in vitro CPE assay (Fig 8B). 
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(A) 
 
(B) 
 
Figure 8. Schematic representation of recombinant adenovirus vectors 
expressing MART1/mGM-CSF/shmTGF-β2 and cytotoxic activity of viruses. 
(A) Ad3484-CMVp-ΔE1B-CMVp-MART1 (M) is composed of the MART1 
gene in the E1 region of Ad3484-CMVp-ΔE1B. Ad3484-CMVp-ΔE1B 
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-MART1-IRES-mGM-CSF-ΔE3-H1-shmTGF-β2 (MGT) is composed of the 
MART1 and mGM-CSF genes in the E1 region and shmTGF-β2 gene in the E3 
region of Ad3484-CMVp-ΔE1B. (B) The oncolytic activity of these viruses was 
analyzed by in vitro cytopathic effect (CPE) assay. Cells were infected with 
each virus at an MOI of 0.1 to 100 and then cells were stained with 0.5% crystal 
violet. 
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7. Enhanced expression of MART, mGM-CSF, and downregulation of 
mTGF-β2 in MGT virus-infected mouse melanoma cells 
Before progressing to animal tests to further investigate the anti-tumor 
effects of MGT virus, the level of recombinant oncolytic adenovirus-mediated 
MART1, mGM-CSF, and shmTGF-β2 expression was verified. 
B16BL6-CAR/E1B55 cells were infected with C, M, or MGT virus with at an 
MOI of 50. Two days after infection, MART1 was detected by western blotting 
and showed a significant increase in the endogenous cellular expression of the 
virally transduced MART1 (Fig 9A). Furthermore, because MART1 is located 
on the surface of the melanoma cells, its expression was also detected by flow 
cytometric analysis. This analysis showed that the surface expression of 
MART1 was increased on both the M and MGT virus-infected cells (Fig 9B).  
To quantify the expression level of mGM-CSF induced by infection with the 
recombinant adenovirus, B16BL6-CAR/E1B55 cells were infected with C, G, 
or MGT virus at an MOI of 50 and then an mGM-CSF ELISA was performed to 
estimate the mGM-CSF protein concentration in the cell supernatants. The G 
and MGT virus-infected cells showed a significant increase in the secretion of 
the virally transduced mGM-CSF protein (Fig 9C) compared to the C 
virus-infected cells. 
The downregulation of mTGF-β2 transcripts in B16BL6-CAR/E1B55 cells 
was confirmed by real-time-PCR. As shown in Figure 9D, mTGF-β2 mRNA 
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levels were decreased by more than 50% in the T or MGT virus infected 
B16BL6-CAR/E1B55 cells compared to control virus infected cells, while the 
mRNA levels of mTGF-β1 and mTGF-β3 were not changed significantly in the 
treated cells. Notably, the secreted level of mTGF-β2 protein was also 
significantly decreased in T and MGT virus-infected cells compared to the C 
virus-infected cells (Fig 9E). 
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(C)                                          
 
(D)                               
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(E) 
  
Figure 9. The expression levels of MART1, mGM-CSF, and shmTGF-β2 in 
virus infected cells. (A) B16BL6-CAR/E1B55 cells were infected with the C, M, 
or MGT virus at an MOI of 50. Two day after, MART1 endogenous expression 
level was detected by western blot. Actin was used as a loading control. (B) 
MART1 cell-surface expression level was detected by flow cytometric analysis. 
(C) To examine mGM-CSF level, B16BL6-CAR/E1B55 cells were infected 
with the C, G, or MGT virus at an MOI of 50. Two days after infection, 
mGM-CSF expression level was measured in the culture supernatants by 
ELISA. To examine mTGF-β mRNA and protein levels, B16BL6-CAR/E1B55 
cells were infected with the C, T, or MGT virus at an MOI of 50. Two days 
after infection, mTGF-β mRNA levels were estimated by real-time-PCR (D) 
and mTGF-β2 protein level was measured in the culture supernatants by ELISA 
(E). 
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8. In vivo effects of combination treatment with recombinant MART1 
plasmid with recombinant oncolytic adenovirus expressing MART1, 
mGM-CSF, and shmTGF-β2 
After observing the gene expressions of recombinant adenovirus in cell 
culture, the next step was to evaluate the anti-tumor effects of MART1 plasmid 
priming together with the oncolytic adenovirus expressing MART1, mGM-CSF 
and shmTGF-β2 (MGT virus). To determine whether the MART1 plasmid 
together with the MGT virus could protect mice from tumor growth, C57BL/6 
mice were subcutaneously injected with B16BL6-CAR/E1B55 mouse 
melanoma cells in the abdomen. Four days after the injection of tumor cells, 
mice were injected once intramuscularly with 50 μg of the pVAX1-MART1 
plasmid. When tumors reached the size range of 70–90 mm3, mice were 
intratumorally injected with PBS, C virus, M virus or MGT and the effects were 
monitored (Fig 10A). As shown in Figure 10B, the growth rate of tumors in 
mice immunized with the MART1 plasmid and the C virus was slightly delayed 
compared with mice treated with the MART1 plasmid and PBS. In contrast, the 
tumors of mice receiving both the MART1 plasmid and the MGT virus had 
significantly delayed growth compared to mice treated with the C virus or M 
virus alone, but tumor regression was not induced (Fig 10B). Images of 
representative virus-treated tumors can be found in Figure 11. Although mice 
treated with the MGT virus had delayed tumor growth and some even had 
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minor tumor regression, the size of the tumors still increased over time after day 
23. In particular, the combination treatment of MART1 plasmid together with 
the M virus alone did not induce an effective anti-tumor response. It is possible 
that these minimal results were caused by only administering a single injection 
of MART1 plasmid as a booster, an amount that may not be sufficient to induce 
a strong mouse melanoma antigen-specific immune reaction. 
To analyze the infection rate of the adenovirus vector and the infiltration of 
immune cells to tumor tissues following the injection of MART1 plasmid and 
adenovirus, histologic analysis of the tumor site was performed. Notably, many 
of the tumor tissues in the mice treated with MART1 plasmid and either C virus, 
M virus, or MGT virus were found to express adenovirus-specific protein, 
whereas those in the PBS-treated group did not (Fig 12). Furthermore, in the 
MART1 plasmid + MGT virus-treated group, many of the tumor tissues were 
observed to have increased lymphocytic infiltration compared with the tumor 
tissues of the groups treated with MART1 plasmid and C or M virus. To 
identify the types of immune cells that had infiltrated into the tumor tissues, 
tumor sections were examined by immunohistochemical analysis using 
anti-CD4 or anti-CD8 monoclonal antibodies. Higher frequencies of CD4+ and 
CD8+ T cells were observed in the tumors treated with MART1 plasmid and 
MGT virus compared to those treated with MART1 plasmid and C or M virus 
(Fig 12). However, denser immune cell infiltration was observed only at the 
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borders of the tumor tissues, which likely explains why these treatments did not 
completely protect the mice from tumor development. I believe that the single 
injection of MART1 plasmid was not sufficient to induce a robust immune 
priming effect in the mice, causing the effects of the combination to be muted in 
these experiments. 
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(B) 
 
 
Figure 10. Anti-tumor effect of the combination treatment of MART1 plasmid 
with adenovirus expressing MART1, mGM-CSF, and shmTGF-β2. (A) 
Experimental design diagram. C57BL/6 mice were injected with 7 × 10
5
 
cells/100 μL of B16BL6-CAR/E1B55 on day -5 and treated with intramuscular 
injections of 50 μg/50 μL of MART1 plasmid into the rear quadriceps on day -2. 
C57BL/6 tumor-bearing mice were treated with intratumoral injections of 1 × 
10
9
 PFU/50 μL of adenovirus on day 1, 3, and 5. (B) Tumor volume was 
monitored and recorded every 2 days until the end of the study. Values 
represent the mean ± SE (5 animals per group). 
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Figure 11. Tumor xenografts. Pictures of C57BL/6 tumor-bearing mice treated 
with virus were obtained at day 14, 18, and 28. 
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Figure 12. Immunohistochemical analysis of recombinant adenovirus infected 
tumor sections. C57BL/6 mice were injected with 7 × 10
5
 cells/100 μL of 
B16BL6-CAR/E1B55 on day -5 and treated with intramuscular injections of 50 
μg/50 μL of MART1 plasmid into the rear quadriceps on day -2. C57BL/6 
tumor-bearing mice were treated with intratumoral injections of 1 × 10
9
 PFU/50 
μL of adenovirus on day 1, 3, and 5. Tumors were collected at day 11 for 
histological analysis. Paraffin-embedded sections of tumor tissue were stained 
with anti-adenovirus type 5 (top row, original magnification: ×200), anti-CD8 
(second and third row, original magnification: ×200 and ×400), and anti-CD4 
(fourth and fifth row, original magnification: ×200 and ×400) antibodies. 
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9. Immune priming/boosting effect of repeated administration of MART1 
plasmid and treatment with recombinant adenovirus expressing MART1 
To test the hypothesis that a single injection of MART1 plasmid did not 
sufficiently prime/boost the immune system enough to protect mice against 
melanoma, the effect of repeated injections of MART1 plasmid was 
investigated. The repeated administration of MART1 plasmid did in fact 
enhance the anti-tumor effects of the adenoviral treatment in the isolated 
splenocytes compared to a single injection of MART1 plasmid (Fig 13A). 
Furthermore, using an interferon (IFN)-γ ELISPOT assay, I determined that 
repeated injections of MART1 plasmid could generate a stronger mouse 
melanoma antigen-specific immune response via increased IFN-γ production 
(Fig 13B, C). Following these results, the in vivo anti-tumor effect of treatment 
with MART1 plasmid and the MGT virus was investigated again, with the 
experimental conditions changed to include repeated injections of the MART1 
plasmid into mice. 
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Figure 13. Effect of repeated administration of the MART1 plasmid. The 
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anti-tumor effect of repeated injection of MART1 plasmid was determined by 
ex vivo experiment. C57BL/6 mice were injected with 7 × 10
5
 cells/100 μL of 
B16BL6-CAR/E1B55 on day -7 and treated with intramuscular injections of 50 
μg/50 μL of MART1 plasmid into the rear quadriceps on day -14, -10, and -6 
(three times injection group) or treated with intramuscular injections of 50 
μg/50 μL of MART1 plasmid on day -6 (one time injection group). C57BL/6 
tumor-bearing mice were treated with intratumoral injections of 1 × 10
9
 PFU/50 
μL of M virus on days 1, 3, and 5. Six days after the last virus injection, 
splenocytes were isolated from mice. (A) B16BL6 cells were incubated with 
splenocytes for 4 h and the splenocyte cytotoxic activity was then measured by 
LDH assay. (B) Splenocytes were stimulated with B16BL6 cell lysate for 24 h 
and IFN-γ ELISPOT assays were then carried out. The number of spots was 
counted at a concentration of 1 × 10
4
 splenocytes. Each value represents the 
mean spot number ± SE of triplicates from a representative experiment. The 
experiment was repeated twice. (C) Representative examples of spot-forming 
cell response. 
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10. Enhanced anti-tumor effects and survival rate following repeated 
MART1 plasmid injections combined with MGT virus treatment 
C57BL/6 mice were injected intramuscularly with 50 μg of the 
pVAX1-MART1 plasmid two times before tumor cell injection and one time 
after the injection of tumor cells into the rear quadriceps, with each injection 
separated from the others by a 4-day interval. When tumors reached the size 
range of 70–90 mm3, mice were intratumorally injected with PBS, C virus, M 
virus, or MGT virus in order to compare the anti-tumor effects of MART1 
plasmid and M virus with those of MART1 plasmid and MGT virus (Fig 14A). 
The tumor volumes by day 15 following viral treatment were 4190.9 ± 882.5 
mm
3
 (PBS), 627.7 ± 196.3 mm
3
 (C virus), 137.7 ± 66.9 mm
3
 (M virus), 384.9 ± 
150.4 mm
3
 (GT virus), and 0.7137 ± 0.7137 mm
3
 (MGT virus). Notably, the 
decrease in tumor growth in the C virus-treated mice was likely caused by the 
tumor-cell-specific lysis induced by the oncolytic adenovirus. However, the 
tumor volumes of mice treated with adenovirus alone (C virus) increased over 
time (Fig 14B).  
In the group treated with MART1 plasmid and M virus, the tumors of two 
mice disappeared by day 17. In contrast, the tumor volumes of the three other 
mice in this group increased over time after day 15 (Fig 14B, 15A), indicating 
that overall tumor growth was decreased compared to the PBS- and C 
virus-treated groups. This phenomenon is likely related to an increase in the 
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mouse melanoma antigen-specific immune reaction. In cell culture, the 
cytotoxicity of this treatment in splenocytes (isolated from mice treated with 
MART1 plasmid and M virus) co-cultured with B16BL6 cells was increased 
compared to those isolated from mice injected with MART1 plasmid with C 
virus. However, there was no effect of treatment with MART1 plasmid together 
with M virus in the LLC cell line, indicating that this human MART1 induced 
immune activation is in fact specific to mouse melanoma antigen (Fig 16A). In 
addition, a remarkably high frequency of cells producing IFN-γ was observed in 
mice treated with MART1 plasmid and M virus compared to mice receiving 
PBS, C, or GT virus (Fig 16B, C). 
Interestingly, in the group treated with MART1 plasmid and MGT virus, 
tumor growth did not occur in four of the five mice, and the injected tumor cells 
of those four mice had been completely eliminated by day 15, while the tumor 
of the fifth mouse was gone by day 22 (Fig 14B, 15A). These data indicate that 
a synergistic relationship exists between the mGM-CSF, shmTGF-β2, and 
MART1-induced mouse melanoma antigen-specific immune response. The 
cytotoxic activity of splenocytes isolated from mice treated with MART1 
plasmid together with MGT virus was strong and the frequency of cells 
producing IFN-γ was highest in the mice treated with MART1 plasmid together 
with MGT virus (Fig 16). Immunohistochemical analysis also showed that a 
higher frequency of NK cells, NK T cells, dendritic cells, and macrophages (all 
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of which were identified as NK1.1 or CD11b+c positive) infiltrated the tumors 
treated with MART1 plasmid and MGT virus compared to those treated with 
MART1 plasmid and C or M virus (Fig 17). 
In addition, the survival rate of mice treated with MART1 plasmid and 
MGT virus was greatly improved, even more so than the MART1 plasmid and 
M virus-treated group (which was also increased), compared to mice treated 
with MART1 plasmid and the C virus or GT virus alone. Further, 100% of the 
animals that received repeated MART1 plasmid treatments and injection of 
MGT virus were still viable 43 days after the initial virus treatment without any 
recurring tumor growth (Fig 15B). Taken together, these results indicate that the 
combination of repeated MART1 plasmid treatment together with MGT virus 
injection is a very effective anti-tumor therapy for malignant melanoma. 
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(A) 
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Figure 14. Anti-tumor effects induced by treatment with the recombinant 
MART1 plasmid and the recombinant oncolytic adenovirus expressing MART1, 
mGM-CSF, and shmTGF-β2. (A) Experimental design diagram. C57BL/6 mice 
were injected with 7 × 10
5
 cells/100 μL of B16BL6-CAR/E1B55 on day -7 and 
treated with intramuscularly injections of 50 μg/50 μL of MART1 plasmid into 
the rear quadriceps on day -14, -10, and -6. C57BL/6 tumor-bearing mice were 
treated with intratumoral injections of 1 × 10
9
 PFU/50 μL of PBS, C, M, GT, or 
MGT virus on day 1, 3, and 5. (B) Tumor volume was monitored and recorded 
every 2 days until the end of the study. Values represent the mean ± SE. 
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Figure 15. Tumor growth and consequent survival rate of tumor-bearing mice. 
(A) Pictures of tumors were obtained on day 15, 21, and 35. (B) Survival rate of 
mice given PBS, C, M, GT, or MGT virus until day 43. One hundred percent of 
the animals that received MART1 plasmid and the MGT virus and 40 % of the 
animals that received MART1 plasmid and the M virus were still alive on day 
43 without tumor occurrence and metastasis. 
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Figure 16. Enhanced mouse melanoma antigen-specific anti-tumor activity of 
immune cells. C57BL/6 mice were injected with 7 × 10
5
 cells/100 μL of 
69 
 
 
 
B16BL6-CAR/E1B55 on day -7 and treated with intramuscular injections of 50 
μg/50 μL of MART1 plasmid into the rear quadriceps on day -14, -10, and -6. 
C57BL/6 tumor-bearing mice were treated with intratumoral injections of 1 × 
10
9
 PFU/50 μL of PBS, C, M, GT, or MGT virus on day 1, 3, and 5. Six days 
after the last virus injection, the splenocytes were isolated and collected. (A) 
B16BL6 and LLC cells were incubated with splenocyte for 4 h and the 
splenocyte cytotoxic activity was then measured by using a LDH assay 
(Effector : Target = 10 : 1). (B) Splenocytes were stimulated with B16BL6 cell 
lysate for 24 h and IFN-γ ELISPOT assays were then carried out. The number 
of spots was counted at a concentration of 1 × 10
4
. Each value represents the 
mean spot number ± SE of triplicates of a representative experiment. The 
experiment was repeated twice. (C) Representative examples of spot-forming 
cell response. 
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Figure 17. Detection of infiltrated immune cells by immunohistochemistry. 
C57BL/6 mice were injected intramuscularly with 50 μg of pVAX1-MART1. 
Injections were performed twice before tumor injection and once after tumor 
injection into the rear quadriceps, separated by a four-day interval. When 
tumors reached a range of 70–90 mm3, mice were intratumorally injected with 
PBS, C, M, or MGT virus. Tumors were collected at day 11 for histological 
analysis. Paraffin-sections of tumor tissue were stained with anti-NK1.1 (top 
and second row, original magnification: ×200 and ×400) and anti-CD11b+c 
(third and fourth row, original magnification: ×200 and ×400) antibodies. 
NK1.1 is a key marker of NK and NKT cells. CD11b is a key marker of 
macrophages and CD11c is a key marker of dendritic cells. 
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IV. DISCUSSION 
 
Cancer therapies, such has radiation and chemotherapy, often rely on toxic, 
non-specific treatments or compounds that can compromise patient health. 
Further, for patients with late stage cancer, such as malignant melanoma, the 
feasible treatment options are even more limited and often result in poor 
prognosis and/or relapse. In this study, I have analyzed the effectiveness of 
MART1 plasmid pre-treatment and injection of oncolytic adenovirus expressing 
MART1, GM-CSF, and shTGF-β2 to induce an anti-melanoma immune 
response. In doing so, I have not only highlighted the necessary protocol for 
immunogene treatment of this tumor type (e.g., use of adenovirus, 
priming/boosting the immune system with MART1 plasmid, injection site, etc.), 
but I have also identified a potent combination treatment (MART1, GM-CSF, 
and shTGF-β2 expressed in an oncolytic adenovirus) to combat tumor growth in 
a mouse model. 
In this investigation, I have circumvented the poor adenoviral transduction 
efficiency in murine tumors, which is one of the major limiting factors for in 
vivo experiments, by using an engineered murine melanoma cell line. Poor 
transduction of the adenoviral vectors is likely due to the limited expression of 
the adenovirus type 5 receptors, the coxsackievirus and adenovirus receptor 
(CAR), and αvβ3 and αvβ5 integrins on the surface of mouse tumor cells. Lack 
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of these receptors is likely to blame for why oncolytic adenovirus has been 
found to only induce a low level of cell lysis in mouse tumor cells. To 
overcome this limitation, the B16BL6-CAR/E1B55 mouse melanoma cell line 
expressing CAR and E1B55 was developed, and shown to effectively replicate 
oncolytic adenovirus (Fig 2) 
48
. This cell line, in addition to in vivo animal 
models, is an essential asset to the field of research investigating 
adenovirus-mediated treatment of melanoma. Notably, this low adenovirus 
infection efficiency in mouse tumor cells is not an issue in human tumor cells, 
which do express the necessary cell surface receptors. 
Ad-3484-CMVp-ΔE1B is a replication-competent adenovirus that contains 
the early region 1A (E1A) gene, which is controlled by the CMV promoter, but 
lacks the E1B gene (Fig 4B). The tumor-specific lytic activity (oncolysis 
activity) of this adenovirus is modulated by the presence of the E1A gene and 
absence of the E1B55 gene. Further, the proteins encoded by the E1A gene of 
human adenovirus type 5 activate viral transcription and re-program cellular 
gene expression in the infected cells, thereby providing an optimal environment 
for viral replication 
49
. E1A binding to retinoblastoma protein (Rb) is also 
critical for the upregulation of adenovirus E2 gene expression and 
transcriptional activation of cell cycle S-phase entry genes 
50,51
. Therefore, the 
E1A gene contained in this specific adenovirus can induce active viral 
replication in infected cells, resulting in efficient gene transfer. 
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Notably, in a normal, non-malignant cell, p53 functions as an anti-viral 
defense by inducing growth arrest or apoptosis 
52
. However, most viruses come 
equipped with several early gene products that prevent p53 from performing 
this function. For example, the E1B 55-kDa and E4 Orf6 proteins as well as 
several other cellular proteins can form an E3 ubiquitin ligase that targets p53 
for proteasomal degradation 
53-55
. The E1B 19-kDa protein is also known to 
block apoptosis downstream of p53 
56,57
, while the E4 Orf3 protein can prevent 
the transcription of p53-dependent genes 
58
. The engineered adenovirus 
construct used in this study expresses E1A, allowing viral replication to occur, 
but does not express E1B55 gene. Thus, this virus will only induce active viral 
replication in cells with inactive or mutated p53 as this is the only environment 
that will allow this specific adenovirus to function. Interestingly, approximately 
90% of all human melanomas contain inactivated wild-type p53, but the 
underlying mechanisms of its inactivation are not fully understood 
59
.  
Several studies have reported the mechanistic details of p53 inactivation in 
various melanoma cell lines, several of which have a mutation in the BRAF
V600E
 
gene as well 
60
. In addition, p53 inactivation has also been achieved with a 
deletion in the p16
ink4a
 locus and mutation of the p14
ARF 
gene 
59,61,62
. While the 
mechanism of p53 inactivation in melanoma tumor cells has not been full 
elucidated, the lack of functional p53 in these malignant tumor cells should, 
theoretically, allow the Ad-3484-CMVp-ΔE1B virus to induce active oncolysis. 
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However, despite the oncolytic activity of the recombinant adenovirus, only 
slight tumor regression was observed in mice receiving the control oncolytic 
adenovirus (Fig 7B, 10B, 14B). It is likely that this muted effect is a result of 
innate anti-viral immunity in the host. An innate anti-viral response is initiated 
by the infected cell while simultaneously releasing chemokines to attract 
neutrophils, mononuclear, and NK cells 
63
. The innate immune response to 
adenovirus can also result in reduced spreading of the virus 
64
. Thus, in order to 
utilize adenovirus as a cancer therapy option in these cells, it is essential to 
overcome this immune tolerance to the virus.  
B16BL6 mouse melanoma cells, the cell type used in this study, are known 
to express a high level of melan-A, but when injected into mice to induce tumor 
formation, the host’s immune tolerance to the self-antigen (melan-A) only 
permits a weak immune response to the B16BL6 tumors 
65
. To overcome this 
and induce an anti-B16BL6 tumor immune response, human MART1 plasmid 
was administered to mice as a DNA vaccine. The results of this priming 
vaccination indicate that human MART1 plasmid is sufficient to generate an 
immune response that can protect the host against mouse melanoma (Fig 3). 
The basis of this cross-species protective response may rely on the nearly 70% 
shared amino acid sequence or the 30% non-homologous amino acid sequence 
28,66
. The human MART1 sequence may also contain shared peptides that 
efficiently bind to the C57BL/6 MHC class I molecules (H-2b) in the muscle 
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cells, allowing it to stimulate an effective response against the murine melan-A 
expressed by the B16BL6 cells. Furthermore, to induce a stronger and 
longer-lived mouse melanoma antigen-specific immune response, the human 
MART1 plasmid and the recombinant adenovirus vector expressing MART1 
were administered to tumor-bearing mice. A comparatively strong anti-tumor 
effect of the MART1 plasmid together with the MART1 adenovirus against 
B16BL6 mouse melanoma was observed in cell culture (Fig 13). However, the 
immune priming/boosting effect of the single MART1 plasmid injection 
together with MART1 recombinant virus treatment in the animal model was 
relatively weak (Fig 10). 
The repeated administration of MART1 plasmid would have the potential to 
induce a prolonged, stronger antigen-specific immune response at the time of 
tumor development. In fact, re-exposure to MART1 by repeated injections was 
shown to induce an enhanced immune response and anti-tumor effect on 
splenocytes compared with a single injection (Fig 13). Moreover, it seems likely 
that the frequency and timing of the MART1 plasmid injections are important 
for the duration and strength of the resulting immune response, particularly 
because B16BL6 mouse cells grow very fast. This accelerated level of cellular 
growth essentially negates the anti-tumor effect of the DNA vaccine injected 
after tumor formation as the immune response would not be induced fast 
enough to catch up with the rapid tumor cell proliferation. Pre-injection of DNA 
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before tumor formation was, therefore, essential in order to have any substantial 
immune system-mediated effect on tumor growth. Notably, in order to 
demonstrate whether the MART1 plasmid administered post-tumor 
development is an effective therapeutic vaccine, an alternative animal 
model/tumor cell line would need to be utilized. Additional work is necessary to 
address this specific treatment option. 
Although pre-treating mice with the MART1 plasmid and following up with 
a post-tumor injection of MART1 expressing adenovirus appeared to induce an 
anti-tumor immune response, it is likely that these effects can be supplemented 
with other genes to further reduce tumor size. In this study, I have focused on 
the addition of GM-CSF, which stimulates a non-specific immune response, and 
silencing of TGF-β, which inhibits tumor cell survival, growth, and immune 
evasion.  
The adenovirus-mediated expression of mGM-CSF was used to further 
stimulate the immune system in response to the malignant melanoma. And I 
chose to focus on the combined use of GM-CSF with TGF-β silencing. TGF-β 
is known to inhibit Th1, macrophage, and neutrophil differentiation and 
development in the tumor microenvironment 
42
. In addition, TGF-β suppresses 
the function of cytotoxic T-lymphocytes, NK cells, and dendritic cells 
42
. 
Increased expression of each of the three TGF-β isoforms has also been 
observed in various cancers. For example, high levels of TGF-β1 have been 
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detected in the gastric mucosa of gastric cancer patients and their first-degree 
relatives 
67
. Further, the expression levels of TGF-β1, TGF-β2, and TGF-β3 are 
also markedly increased in hepatocellular carcinoma (HCC) 
68
. Overexpression 
of TGF-β2 and TGF-β3 in cholangiocarcinoma has also been shown to promote 
tumor cell proliferation 
69
, while the overexpression of TGF-β contributes 
significantly to the development of pancreatic cancer 
70
. Notably, these reports 
suggest that the active isoform of TGF-β may be dependent on the type of 
cancer.  
To this end, our laboratory has performed experiments highlighting the 
suppression of TGF-β1 expression in breast cancer cells as well as the 
anti-pancreatic cancer effects of TGF-β2 expression. In the present study, 
shRNA was used to suppress the expression of TGF-β1 and TGF-β2, as these 
are the two isoforms expressed in the majority of malignant melanomas 
71,72
. 
Although suppressing TGF-β expression would be expected to strongly inhibit 
tumor growth and survival, when the expression of TGF-β1 experimentally 
decreased, the reduction of signaling molecules involved in cell growth, 
survival, and metastasis were modest (Fig 5). However, silencing TGF-β2 
resulted in a much more pronounced level of reduced expression for these 
downstream signaling molecules. Consequently, decreasing both TGF-β1 and 
TGF-β2 did not appear to be necessary to cure malignant melanoma, and it is 
clear that TGF-β2 is the major player among the three TGF-β isoforms 
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expressed by B16BL6 cells.  
Furthermore, when TGF-β2 was silenced in combination with 
GM-CSF-mediated activation of the immune system an enhanced anti-tumor 
response was achieved. This effect was further exacerbated when used in 
combination with MART1 pre-treatment and MART1-expressing adenovirus 
injection. When the mice were treated with MART1 plasmid and injected with 
an oncolytic adenovirus expressing shTGF-β2, mGM-CSF, as well as MART1, 
this anti-tumor response included a higher frequency of various immune cells 
(CD4+, CD8+ T cells, NK cells, NK T cells, dendritic cells, and macrophages) 
in the tumors as well as an increase in tumor cell death compared to tumors 
treated with MART1 plasmid and empty adenovirus or adenovirus containing 
only one gene. These data suggest that a potent immune reaction can be induced 
using multiple immune modulating genes, repeated pre-tumor boosts to the 
immune system, and anti-tumorigenesis genes.  
 
 
 
 
 
 
 
79 
 
 
 
V. CONCLUSION 
 
Combination immunogene therapy, which uses the simultaneous expression 
of diverse immune modulating genes, appears to be more effective at treating 
cancer compared with single gene treatments. In this study, I have stimulated 
immune cells with MART1, a human melanoma antigen that can induce 
cross-reactivity with the mouse melan-A melanoma antigen, consequently 
inducing a melan-A-specific anti-tumor effect in my mouse tumor model. I have 
also shown that the combination of tumor antigen-specific induction with 
MART1 (pre- and post-tumor), general immune stimulation with GM-CSF, 
shTGF-β2-mediated anti-tumor effects, and oncolytic function of adenovirus 
was more potent than the anti-tumor effects of each treatment alone. 
Consequentially, I believe that this treatment combination could be used as a 
feasible therapeutic strategy for the malignant melanoma. 
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ABSTRACT (IN KOREAN) 
 
악성 흑색종에서 DNA백신과 
면역조절 유전자들을 발현하는 종양살상 아데노바이러스의 
병합치료에 의한 항 종양 효과 
 
<지도교수 김주항> 
 
연세대학교 대학원 의과학과 
 
김 소 영 
 
 
암에 대한 면역 치료법은 환자 몸의 면역 체계를 활성화 
시킴으로써 암 세포만을 특이적으로 제거하는 치료방법이다. 
하지만, 암 세포들은 여러 가지 전략을 사용하여 면역 체계를 
피해가며, 면역 체계가 활성화 되었더라도 활성화된 항종양 
면역 반응으로부터 도피 할 수 있는 능력 또한 갖고 있기 
때문에 항암 면역 치료에 많은 한계를 드러내고 있다. 따라서 
이러한 한계를 극복하는 치료제를 개발하는 것이 암 치료를 
위한 과제라고 할 수 있다. 또한 환자의 세포매개면역뿐만 
아니라 체액성면역을 동시에 유도하는 기능은 부작용 없이 
강력한 치료 효과를 유발하기 위해 면역치료제가 갖추어야 하는 
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기능이다.  
본 연구에서는 human MART1 유전자와 MART1을 발현하는 
아데노바이러스를 이용하여 강력한 흑색종 항원 특이적인 
면역반응을 유도 하고자 하였다. Human MART1과 mouse melan-A 
는 약 70%의 유전자 서열이 일치하기 때문에 이종간의 교차 
반응성에 의해 MART1을 항원으로 인식한 면역세포들이 
동물모델에서 melan-A를 인식하여 항 종양효과를 나타낼 수 
있다. 이 경우 MART1에 의해서 유발된 강력한 면역반응은 
자가 항원인 melan-A에 대한 면역 관용을 극복하고 다양한 
면역세포로 하여금 흑색종 세포를 공격하도록 유도할 수 있다.  
이와 동시에 전반적인 면역반응의 활성화를 위해 MART1을 
발현하는 아데노바이러스에 대식세포, 수지상세포등 다양한 
면역세포의 활성화를 유도하는 GM-CSF, 그리고 암세포의 
성장과 생존기능을 억제하고, 면역회피 작용을 억제하는 
TGF-β2에 대한 shRNA를 추가적으로 탑재하였다. 
먼저 각 유전자를 삽입한 아데노바이러스의 항 종양효과를 
확인한 결과 GM-CSF나 shTGF-β2를 각각 단독으로 탑재한 
경우보다 GM-CSF와 shTGF-β2를 동시에 탑재한 경우 
면역세포의 활성화를 유도하는 기능도 증가하고 종양세포의 
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성장을 억제하는 효과로 인해 결과적으로 항 종양 효과가 
증가하는 것을 동물실험을 통해 확인하였다. 이 결과를 통해 
한가지 치료용 유전자를 사용하는 것보다 여러 유전자를 함께 
사용하는 것이 더 효과적임을 알 수 있었다. 그리고 MART1, 
GM-CSF, shTGF-β2를 모두 발현하는 종양살상 아데노바이러스와 
MART1 백신 유전자의 근육 주사를 함께 처리하여 항원 특이적 
면역반응의 활성화, 전반적인 면역 반응의 활성화, 종양세포의 
성장 억제, 종양세포 특이적인 세포용해를 모두 유도하여 항 
종양 효과를 얻고자 하였다. MART1 백신 유전자를 종양이 
형성되기 전, 후에 각각 2회, 1회 근육주사로 주입한 후 MART1, 
GM-CSF, shTGF-β2를 모두 발현하는 종양살상 아데노바이러스를 
종양에 직접 주입하였다. 그 결과 모든 생쥐에서 종양이 점점 
줄어들다 바이러스 처리 후 22일 전후 시점에서 종양이 모두 
없어졌으며 실험용 생쥐의 100% 생존율을 확인할 수 있었다. 
이러한 효과는 다양한 in vitro, in vivo, ex vivo 실험을 통하여 
MART1 백신 유전자와 MART1, GM-CSF, shTGF-β2를 모두 
발현하는 종양살상 아데노바이러스를 동시에 처리 함으로서 
얻어지는 항 종양 면역반응의 증가임을 확인 하였다. 다만 
종양살상 아데노바이러스에 의한 종양 세포 특이적인 세포 
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용해기능은 바이러스에 대한 면역반응으로 인해 바이러스 주입 
후 초기에만 제한적으로 나타난 것으로 생각된다. 비록 
초기에만 제한적으로 그 효과가 나타났지만 연구결과 얻어진 항 
종양효과에 긍정적인 영향을 제공한 것으로 생각된다. 
결과적으로 본 연구를 통해 다양한 면역조절 유전자를 적절히 
조화시켜 사용하는 것은 항 종양 면역유전자 치료법 개발에 
좋은 방법임을 확인할 수 있었다. 또한 MART1 유전자 백신, 
그리고 MART1, GM-CSF, shTGF-β2를 동시에 발현하는 종양살상 
아데노바이러스를 함께 사용하는 병용요법 (combination 
therapy)은 악성 흑색종을 치료하고 환자의 생존율을 증가시키기 
위한 치료법으로 이용 될 수 있다는 가능성을 제시하였다. 
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